CT26-hPD-L1
Strain Information
Validation Data
Figure 1. hPDL1 expression in wild-type CT26 and CT26-hPDL1 cell lines.
Figure 2. Tumor growth curve of CT26-hPDL1 syngeneic model (n=3).
Figure 3. The expression of hPDL1 in humanized modified tumors by FACS.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more